Covid-19 News update: DCGI approves Johnson & Johnson single-dose vaccine for adolescents aged 12-17 years
The Drug Controller General of India (DCGI) has approved the Johnson & Johnson single-dose vaccine for children aged 12 to 17 in India.
The single-shot Covid vaccine developed by American pharmaceutical giant Johnson & Johnson showed 85 percent effectiveness in preventing Covid in the third phase of testing.
As a consequence, India has authorised the use of the Johnson & Johnson single dose vaccine in an emergency.
The Covid-19 vaccine, according to a release from Johnson & Johnson India, is a major step in halting the corona pandemic.